HIV pipeline prospects getting healthierThere is no cure for HIV, but with proper medical treatment, the disease can be controlled.
Top 5 pipeline drugs for 2018
Top 5 pipeline drugs for 2018New blockbuster drugs to treat various conditions are expected to be among the top drugs to hit the marketplace in 2018. Here are 5 of the top new drugs in the pipeline for 2018, according to analysts.
FDA approves novel leukemia, hepatitis C drugsFDA approved the first treatment for patients with a certain type of acute myeloid leukemia, as well as 2 new drugs to treat hepatitis C.
Evolving hepatitis C pipeline offers hope to patients
Evolving hepatitis C pipeline offers hope to patientsCost burden prompts payers to consider appropriate utilization
Six ways to combat pharma price gougingDrug price increases can prove challenging for payers. Here’s six strategies to keep in your arsenal.
5 things to know about Gilead’s new hep C drugGilead Sciences, which already makes the leading hepatitis C drugs Harvoni and Sovaldi, recently received priority review from FDA for a new Hepatitis C combination drug.
FDA approves Harvoni for new usesFDA recently approved Harvoni for expanded use in patients with genotype 4, 5 and 6 chronic hepatitis C virus infection – as well as in hepatitis C patients co-infected with HIV.
Top 4 things you need to know about the state of HIV treatmentWhile Gilead works on a “cure,” here are four things managed care executives need to know about the current state of HIV treatment
FDA approves changes to hep C drug label to include new warningsFDA has approved changes to the hepatitis C antiviral simeprevir (Olysio, Janssen) label to include new warnings about serious symptomatic bradycardia—slowing of the heart rate—when co-administered with antiarrhythmic drug amiodarone and antiviral sofosbuvir (Solvaldi, Gilead).
Gilead sues to stop Actavis' generic bid for LetairisActavis plc on Friday said it filed an Abbreviated New Drug Application (ANDA) with the Food and Drug Administration (FDA) seeking approval to market Ambrisentan Tablets, a generic version of Gilead Sciences, Inc.'s Letairis®, a treatment for pulmonary arterial hypertension.